THR-β Modulators for Liver Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) lack effective methods to halt disease progression and reverse fibrosis, which is a major predictor of liver disease evolution, and existing thyroid hormone therapies face challenges in selectively targeting liver metabolism without cardiac side effects.
Innovation Solution
Development of novel compounds that act as modulators of thyroid hormone receptor (THR)-β activity, including agonists and antagonists, specifically designed to target liver-related disorders while minimizing cardiac effects, using structures that are inactive outside the liver and convert to active forms within the liver.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If thyroid hormone receptor agonists are used to treat liver-related disorders, then therapeutic effect on NAFLD and NASH is improved, but cardiac side effects such as heart rate increase and cardiac hypertrophy occur
Solution Approach 1:
The patent divides the thyroid hormone receptor system into two distinct targets: TRβ in the liver (therapeutic target) and TRα in cardiac tissue (side effect source). By designing compounds with selective affinity for TRβ over TRα, the invention segments the pharmacological action to achieve liver-specific effects while sparing cardiac tissue from harmful stimulation.
Solution Approach 2:
The invention creates compounds with differential binding properties to TRα and TRβ receptors based on local tissue requirements. The molecular structure is optimized to have high affinity for TRβ (liver) and low affinity for TRα (heart), thereby providing locally appropriate pharmacological activity - therapeutic in the liver and neutral in the heart.
2Reliability
If TRβ selective agonists are developed to improve therapeutic index, then cardiac safety is improved, but structural similarity between TRβ and TRα ligand-binding domains makes selectivity difficult to achieve
Solution Approach 1:
The patent introduces asymmetry in the molecular structure of TR modulators to exploit subtle differences between TRα and TRβ ligand-binding domains. By creating non-symmetric molecular features (such as specific substituent patterns on the phenyl ring, heterocyclic variations, and asymmetric substitution positions), the compounds achieve differential binding affinity despite the high overall similarity between the two receptor types.
Solution Approach 2:
The invention systematically varies molecular parameters (substituent types, positions, and combinations) to fine-tune selectivity. By changing parameters such as the heterocyclic group (pyridine, pyrimidine, triazine), substituent positions (2,3,5-trimethyl vs. other patterns), and chain lengths, the patent optimizes the balance between TRβ affinity and TRα selectivity.
3Reliability
If prodrugs are designed to convert to active form specifically in the liver, then cardiac stability is improved, but additional metabolic steps are required for activation
Solution Approach 1:
The patent incorporates prodrug design where the active TRβ-modulating compound is pre-masked with a liver-specific activating group. The prodrug circulates in stable form in the blood and extrahepatic tissues, then undergoes enzymatic conversion (typically by hepatic esterases or other liver-specific enzymes) to release the active compound only within the liver, achieving temporal and spatial control of activation.
Data Source
AI summary
Disclosed herein are compounds of Formula I′:or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising such compounds, and methods of treating disease by administering or contacting a patient with one or more of the above compounds.